146 related articles for article (PubMed ID: 6014563)
21. [Neuroleptics in ambulatory practice].
Til E; Vucković S
Med Pregl; 1969; 22(7):395-9. PubMed ID: 5201404
[No Abstract] [Full Text] [Related]
22. [Oral hyperkinesis].
Bogolepov NK; Fleĭs EP
Zh Nevropatol Psikhiatr Im S S Korsakova; 1971 Dec; 71(12):1761-5. PubMed ID: 5143958
[No Abstract] [Full Text] [Related]
23. [Hazards in psychopharmacological treatment and their prevention].
Thiele W
Hippokrates; 1969 Apr; 40(8):302-7. PubMed ID: 5795574
[No Abstract] [Full Text] [Related]
24. Neuroleptic treatment and mortality.
Turunen S; Salminen J
Dis Nerv Syst; 1968 Jul; 29(7):474-7. PubMed ID: 5676130
[No Abstract] [Full Text] [Related]
25. [Current toxicomanias].
Alliez J
Mars Med; 1965; 102(5):421-7. PubMed ID: 5889113
[No Abstract] [Full Text] [Related]
26. [Experimentation with 1317 AN].
Vayron de la Moureyre D; Lehembre P
Lille Med; 1970 Jan; 15():180-3. PubMed ID: 5437222
[No Abstract] [Full Text] [Related]
27. [Psychodynamic and sociodynamic changes produced by methylperidol].
Leal R
Actas Luso Esp Neurol Psiquiatr; 1969 Oct; 28(4):299-305. PubMed ID: 5394271
[No Abstract] [Full Text] [Related]
28. [Advantages and disadvantages of a new group of drugs: long acting neuroleptics].
Simon P
Ann Med Interne (Paris); 1972; 123(8):791-3. PubMed ID: 4642196
[No Abstract] [Full Text] [Related]
29. [A method of developing and testing new antidepressants].
Poeldinger W
Nervenarzt; 1966 Mar; 37(3):121-3. PubMed ID: 6007512
[No Abstract] [Full Text] [Related]
30. [On the limitations and dangers of psychopharmaceutical agents].
De Busscher J
Belg Tijdschr Geneesk; 1965 Sep; 21(17):791-807. PubMed ID: 5317941
[No Abstract] [Full Text] [Related]
31. [Psychotherapeutic agents: their use and abuse].
Pöldinger W
Hippokrates; 1968 Jul; 39(14):524-33. PubMed ID: 5730669
[No Abstract] [Full Text] [Related]
32. [Complications and abuse of psychotropic drugs].
Pichot P; Gautier JC; Lapresle J; Lereboullet J; Péquignot H
Presse Med (1893); 1968 Jan; 76(2):71-4. PubMed ID: 5638160
[No Abstract] [Full Text] [Related]
33. [Secondary effects of psychotropic drugs].
Grenier J
Laval Med; 1968 Sep; 39(7):581-3. PubMed ID: 5744726
[No Abstract] [Full Text] [Related]
34. Psychotropic drugs and the elderly patient.
Dellefield K; Miller J
Nurs Clin North Am; 1982 Jun; 17(2):303-18. PubMed ID: 6919940
[No Abstract] [Full Text] [Related]
35. [Long-term administration of octoclothepin in psychoses--observation of biological parameters].
Svestka J; Náhunek K
Act Nerv Super (Praha); 1970 Jan; 12(1):45. PubMed ID: 5418653
[No Abstract] [Full Text] [Related]
36. [Poisonings by psychopharmacological agents in pediatrics].
Astolfi E; Mariani F
Arch Argent Pediatr; 1965; 63(3):116-9. PubMed ID: 5887084
[No Abstract] [Full Text] [Related]
37. Psychotherapeutic drugs: a guide for rehabilitation workers.
Holzberg SI; Schriemer DA
J Rehabil; 1967; 33(4):18-20. PubMed ID: 6045731
[No Abstract] [Full Text] [Related]
38. Editorial: Cardiotoxicity of psychotrophic drugs.
J Assoc Physicians India; 1973 Sep; 21(9):788-9. PubMed ID: 4794912
[No Abstract] [Full Text] [Related]
39. [Comment about the article "Psychopharmaceuticals and diabetes" of Ress C, Tschoner A, Kaser S, and Ebenbichler CF in Wiener Medizinische Wochenschrift 2011; 161/21-22: 531-42].
Ulrich S
Wien Med Wochenschr; 2012 Dec; 162(23-24):541-2; author reply 543. PubMed ID: 23135252
[No Abstract] [Full Text] [Related]
40. [Psychopharmacologic drugs--wanted and unwanted effects].
Rafaelsen OJ
Nord Med; 1971 Aug; 85(31):933-4. PubMed ID: 5569706
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
